Many children with end stage renal disease develop hyperlipidemia.HMG-CoA reductase
inhibitors, such as pravastatin, are typical treatments for hyperlipidemia. However, we do
not know how pravastatin is metabolized in patients on dialysis. This study is designed to
provide preliminary pharmacokinetic data for pravastatin in pediatric patients on peritoneal
1. Patients from 12 months to 18 years of age.
2. Patients with end stage renal disease who receive continuous cycling peritoneal
3. signed informed consent
4. Physical exam demonstrates no abnormalities that would make this study medically
hazardous to the subject.
1. Any clinically significant unstable medical condition or chronic disease other than
those associated with ESRD.
2. Any clinically significant illness within 10 days or receiving single-sdoe of study
3. History of rhabdomyolysis
4. Clinically significant liver disease or history of malabsorption or previous
gastrointestinal surgery that could effect drug absorption or metabolism.
5. Clinical laboratory abnormalities: AST,ALT, CPK > 2.5 times upper limit of normal;
hemoglobin < 8.5 g.dL.
6. Known hypersensitivity to pravastatin
7. Unwilling to have blood samples drawn
8. Has taken a HMG-CoA reductase inhibitor in the last week -